Novel LUC7L::NUTM1 fusion in PDGFRA-rearranged myeloproliferative neoplasm with eosinophilia: a case report

PDGFRA重排伴嗜酸性粒细胞增多症的骨髓增生性肿瘤中发现新型LUC7L::NUTM1融合基因:病例报告

阅读:1

Abstract

Myeloid/lymphoid neoplasm with PDGFRA rearrangement are a group of haematologic tumors, in which the clonal proliferation of precursor eosinophils leads to persistent eosinophilic hyperplasia, and varying degrees of involvement of the liver, spleen and lymph nodes. While PDGFRA rearrangements are frequently observed in mpn-eo, the co-occurrence of t(15;16)(q14;p13) translocations leading to LUC7L::NUTM1 fusion genes has not been previously documented. Here we present a 30-year-old male patient with leukocytosis and generalized lymphadenopathy. Bone marrow cytology revealed eosinophilia with abnormal and atypical granulocytes showing dysplastic cytoplasmic granules. Cytogenetic analysis identified t(15;16)(q14;p13), while RNA sequencing confirmed the novel LUC7L::NUTM1 fusion gene and co-detected FIP1L1::PDGFRA fusion gene. The patient achieved stable disease imatinib (100 mg/day) treatment. This first report of dual PDGFRA/NUTM1 fusions expands the molecular spectrum of MPN-Eo and highlights the therapeutic implications of novel fusion detection. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12957-026-04298-3.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。